Semaglutide Cuts Fractures 15% in Type 2 Diabetes Patients as Weight Loss Outpaces Rivals
Updated
Updated · Medical News Today · Jun 15
Semaglutide Cuts Fractures 15% in Type 2 Diabetes Patients as Weight Loss Outpaces Rivals
3 articles · Updated · Medical News Today · Jun 15
Summary
A matched study presented at ENDO 2026 linked semaglutide to 794 fractures versus 1,045 in comparator patients with type 2 diabetes, a 15% lower fracture incidence over more than 3.5 years.
Among 17,506 patients in each group, semaglutide also produced the largest BMI decline against phentermine-topiramate, bupropion-naltrexone, and dulaglutide, despite concerns that weight loss can raise fracture risk in diabetes.
The analysis used U.S. electronic health records, with BMI data available for only 4,191 matched pairs, and excluded patients with prior fractures or osteoporosis treatment.
Researchers and outside specialists said the retrospective, non-peer-reviewed findings are hypothesis-generating because residual confounding, missing data, and a mixed control group could affect the apparent bone benefit.